105003-90-5

Basic information

• Product Name: (4-METHOXY-2-NITROPHENYL)ACETONITRILE
• Synonyms: 4-METHOXY-2-NITRO-CYANOMETHYLBENZENE;(4-METHOXY-2-NITROPHENYL)ACETONITRILE;2-(4-Methoxy-2-nitrophenyl)acetonitrile
• CAS NO: 105003-90-5
• Molecular Formula: C₉H₈N₂O₃
• Molecular Weight: 192.17
• Mol File: 105003-90-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (4-METHOXY-2-NITROPHENYL)ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-METHOXY-2-NITROPHENYL)ACETONITRILE(105003-90-5)
• EPA Substance Registry System: (4-METHOXY-2-NITROPHENYL)ACETONITRILE(105003-90-5)

Safety Data

• Hazardous Substances Data: 105003-90-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(4-Methoxy-2-nitrophenyl)acetonitrile is used as a key intermediate for the synthesis of various organic compounds due to its unique reactivity and chemical structure, facilitating the creation of a wide range of products in the chemical industry.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical sector, (4-Methoxy-2-nitrophenyl)acetonitrile is utilized as a precursor in the production of drugs, contributing to the development of new medications and therapeutic agents.
Used in Agrochemical Production:
(4-METHOXY-2-NITROPHENYL)ACETONITRILE also serves as a precursor in the creation of agrochemicals, playing a role in the development of products designed to enhance agricultural productivity and crop protection.
Used in Chemical Research and Development:
(4-Methoxy-2-nitrophenyl)acetonitrile is employed in research and development initiatives, where its potential applications in different industries are explored and expanded upon, driving innovation and advancement in chemical sciences.

Upstream product

• 555-03-3 3-nitroanisole 
• 3598-13-8 (4-chlorophenoxy)acetonitrile 
• 105-56-6 ethyl 2-cyanoacetate 
• 10298-80-3 2-chloro-5-methoxynitrobenzene 
• 57559-52-1 4-methoxy-2-nitrobenzyl bromide 
• 2042-14-0 4-methyl-5-nitrophenol 
• 151-50-8 potassium cyanide 
• 65547-98-0 ethyl 2-cyano-2-(4-methoxy-2-nitrophenyl)acetate 

Downstream Products

• 118671-03-7 2-(2-amino-4-methoxyphenyl)acetonitrile 
• 90923-03-8 (4-methoxy-2-nitro-phenyl)-acetic acid methyl ester 
• 1334784-89-2 (2-acetylamino-4-methoxy-phenyl)-acetic acid methyl ester 
• 1567360-55-7 ethyl 3-cyano-3-(4-methoxy-2-nitrophenyl)propanoate 
• 1567360-56-8 7-methoxy-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonitrile 
• 911416-41-6 [2-(4-methoxy-2-nitrophenyl)ethyl]carbamic acid tert-butyl ester 
• 911416-42-7 [2-(4-methoxy-2-nitro-phenyl)-ethyl]-methyl-carbamic acid tert-butyl ester 
• 911416-43-8 5-methoxy-2-(2-methylaminoethyl)phenylamine hydrochloride 
• 605668-99-3 2-(2-amino-ethyl)-5-methoxy-phenylamine 
• 691900-61-5 C₁₅H₁₂N₂O₂ 
• 691900-59-1 6-methoxy-1H-indazole-3-carbonitrile 
• 1567360-68-2 N-((7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)methyl)-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetamide 

Relevant articles and documents

Antibodies to aripiprazole haptens and use thereof

Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, in

ETHER COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Antibodies to Aripiprazole Haptens and Use Thereof

Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, in

HAPTENS OF ARIPIPRAZOLE AND THEIR USE IN IMMUNOASSAYS

The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from aripiprazole. The invention also relates to

2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES

The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R1, R2, Ra, L, Z, Z1 and Z2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.

TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA

Compounds of formula 1 are disclosed, wherein G, D, A, Q, Y, Z, and R1 through R10 are defined in the specification. Also provided are descriptions of processes for preparing compounds of formula 1, intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relate

OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION

This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also rela

Ophthalmic compositions for treating ocular hypertension

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relate

An aminoisoflavone-salicyloylindole ring transformation

A series of 2′-nitroisoflavones 8-10, 15, 22, 27 and 28 was prepared via the (2-nitro-phenyl)-acetic acids 1, 13, 19 and 25. In order to obtain the corresponding 2′-aminoisoflavones the reduction of 8-10, 15, 22, 27 and 28 was undertaken. Surprisingly, new 3-salicyloylindoles instead of the expected 2′-aminoisoflavones were the main reduction products. In the following paper the preparation of the 2′-nitroisoflavones 8-10, 15, 22, 27 and 28 as well as the reduction experiments obtaining the 2′-aminoisoflavones 33 and 35 and the 3-salicyloylindoles 29-32, 34 and 36 will be described. Furthermore, a possible mechanism responsible for the formation of the 3-salicyloylindoles from 2′-nitroisoflavones under reductive conditions will be discussed.